RESUMEN
Sixty-one of 1676 lunar rock fragments examined were found to be anorthosites, markedly different in composition, color, and specific gravity from mare basalts and soil breccias. Compositional similiarity to Tycho ejecta analyzed by Surveyor 7 suggests that the anorthosites are samples of highlands material, thrown to Tranquillity Base by cratering events. A lunar structural model is proposed in which a 25-kilometer anorthosite crust, produced by magmatic fractionation, floats on denser gabbro. Where early major impacts punched through the crust, basaltic lava welled up to equilibrium surface levels and solidified (maria). Mascons are discussed in this context.
RESUMEN
A biomarker is defined as "a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or biological responses to a therapeutic intervention". Biomarkers can be utilized to detect disease, evaluate treatment risks, or determine treatment effectiveness. In the case of cancer, anthracyclines such as doxorubicin are front-line therapy to treat a number of different malignancies including breast cancer. However, a significant fraction of patients experience drug-induced cardiotoxicity. This toxicity is dose-limiting and can cause long-term morbidity or mortality. There is an unmet medical need to identify patients who are at risk for doxorubicin-induced cardiotoxicity, to detect cardiac damage early so that patient risk can be minimized, and to monitor the success of cardioprotective strategies. Therefore, doxorubicin treatment of cancer is an excellent example of the need for biomarkers to indicate drug safety in addition to drug efficacy. In this review we will discuss the mechanism of doxorubicinassociated cardiotoxicity, as well as other cancer therapies that induce cardiac toxicity by causing oxidative damage. We will also evaluate established and proposed biomarkers for cardiotoxicity based on our evolving knowledge of oxidative damage and subsequent autophagy. Finally, we will discuss advantages of combining oxidative damage- and autophagy-based protein biomarkers with current biomarkers such as troponins to facilitate early detection and mitigation of cardiotoxicity induced by cancer therapeutic agents.